HCLSIG/PharmaOntology/Meetings/2009-07-09 Conference Call

From W3C Wiki

Conference Details

  • Date of Call: Thursday July 9, 2009
  • Time of Call: 12:00pm Eastern Daylight Time (EDT), 17:00 British Summer Time (BST)
  • Dial-In #: +1.617.761.6200 (Cambridge, MA)
  • Dial-In #: +33.4.89.06.34.99 (Nice, France)
  • Dial-In #: +44.117.370.6152 (Bristol, UK)
  • Participant Access Code: 42572 ("HCLS2").
  • IRC Channel: irc.w3.org port 6665 channel #HCLS2 (see W3C IRC page for details, or see Web IRC)
  • Mibbit instructions: go to http://www.mibbit.com/chat and click the server link. Enter irc.w3.org:6665 into that box, enter a nickname, and enter #HCLS2 for the channel
  • Duration: ~1h
  • Convener: Susie

Agenda

  • Review Actions
  • Spreadsheet editing rights - Susie, Elgar
  • Review of Classes and Class Definitions - Colin, Christi, Elgar, Trish, Bosse
  • Review of Use Cases - Colin, Susie, Christi, Michel
  • Material for ICBO/DILS A0 poster at International Conference on BioMedical Ontology - Colin and Holger
  • AOB

Minutes

Attendees: Trish, EricP, Colin, Michel, Bosse, Susie, Hans, Christi

Apologies: Elgar

<michel> Agenda Item: Action Item

<Susie> http://esw.w3.org/topic/HCLSIG/PharmaOntology/Actions

<michel> christi: dils is covered

<michel> christi: need another poster printed for icbo

<michel> colin: could send the poster directly to icbo

<michel> susie: will ping elgar on his work

<michel> colin: samsung will go to icbo

<michel> susie: samson working on drug ontology

<Christi> hans will arrange for printing at manchester (dils)

<michel> susie: Bosse/Elgar to discuss whether phenotype and Sign/Sympton/Observation are effectively the same or are different

<michel> colin: sympton must be reported by patient

<michel> bosse: the only difference is who is observing them

<Colin> http://bioontology.org/wiki/index.php/DallasWorkshop

<michel> susie: new action item is to review dallas workshop and summarize conclusion

<michel> bosse: will add to wiki and invite comments

<michel> susie: michel's pharmacogenomic use case is done

<michel> susie: talk about poster

<michel> colin: left hand side - motivation, goals, methodology

<michel> colin: right hand side - ontology : processes in drug discovery pipeline, cyan "blobs" potential terms

<michel> colin: from molecules to drugs

<michel> colin: formulation use case?

<michel> colin: in addition to actionable role as active ingredient, believes drug role is socially ascribed

<michel> colin: mapped to OBO ontologies

<michel> hans: what do we mean about translational medicine?

<michel> susie: purpose is backbone ontology to perform a query from molecular to clinical

<michel> susie: ontology is in development - first identified key entities that should be included

<michel> susie: collected use cases / questions

<michel> colin: how much of translational medicine process is going to be captured? should we consider things like phase i trial

<michel> susie: if nobody else is capturing this, perhaps we should investigate it, but being a high level bridge would be most useful at this time

<michel> susie: we can feedback to other ontology efforts

<michel> colin: should differentiate between social and biological roles

<michel> hans: will it be used for inter-pharma communication?

<michel> susie: lilly wanted it to be process independent - used to integrate data, processes would be applied over the data

<michel> colin: add this to poster

<michel> susie: represent health care environment, clinical availability of drug

<michel> trish: who is going to DILS?

<michel> susie: Hans is going to present the poster, Jun Bao (sp?)

<michel> colin: need some clinical oriented process terms

<michel> colin: prescription, diagnosis

<michel> susie: Chimezie's clinical patient record ontology?

<michel> hans: should we be looking into the approval process, etc

<haco> medical need, product decision, FDA registration, FDA approval

<haco> roles: Health Care Professionals, Payers, Providers

<haco> important missing term is "candidate"

<michel> general practitioner

<michel> will make recommendations to see specializts

<michel> susie: lab technician - take samples etc

<michel> hans: what does it look like from a patient perspective

<michel> susie: these kinds of aspects were identified in the roles document

<michel> colin: need new figure to deal with the players / patient centric bit

<michel> susie/colin: not all of it is patient centric

<michel> hans: very pharmaceutical oriented

<michel> susie: lose the lead optimization

<haco> target - hit - lead- candidate - drug as major phases

<michel> colin: diagnosis - treatment - cure

Retrieved from "https://www.w3.org/wiki/index.php?title=HCLSIG/PharmaOntology/Meetings/2009-07-09_Conference_Call&oldid=32824"